e e ectiveness of treatment of renal diseases is limited because the lack of diagnostic, prognostic and therapeutic markers. Despite the more than a decade of intensive investigation of urinary biomarkers, no new clinical biomarkers were approved. is is in part because the early expectations toward proteomics in biomarkers discovery were signi cantly higher than the capability of technology at the time. However, during the last decade, proteomic technology has made dramatic progress in both the hardware and so ware methods. In this review we are discussing modern quantitative methods of mass-spectrometry and providing several examples of their applications for discovery and validation of renal disease biomarkers. We are optimistic about future prospects for the development of novel of speci c clinical urinary biomarkers.
Introduction
Currently the e ectiveness of treatment of renal diseases is limited by the lack of diagnostic, prognostic, and therapeutic markers. A renal biopsy is o en necessary to establish a diagnosis, particularly in the case of glomerular diseases. Renal biopsy is a highly invasive method associated with high morbidity and mortality. In contrast, urine is an easily accessible bio uid and its protein content is derived mainly from the kidney and low urinary tract organs.
us, urinary biomarkers are an attractive tool for development of clinical tests. Recently mass-spectrometry (MS) is playing an increasing role in the identi cation and quanti cation of biomarkers [1] [2] [3] [4] [5] [6] . Despite its promise, the translation of urinary biomarkers into the clinic has been ine cient [7] . Part of the problem can be attributed to the underestimating of e orts required to discover novel biomarkers and underdevelopment of MS technology. ere are several major obstacles for the development of clinically relevant urinary biomarkers [8] . Both the nature of urine and the MS techniques are responsible for generation of non-reproducible results.
ere is no standard protocol for urine collection and storage, concentration of samples, protein isolation and sample preparation for MS [9] [10] [11] . Urine has a high level of variability in volume and protein concentration. Urine composition depends on diet, circadian rhythms, age, gender and exercise [11] [12] [13] [14] [15] . Because MS-based methods are very sensitive and capable of detection of femtomoles of peptides, di erent methods for urine collec-tion, concentration and protein isolation can yield distinct proteins discovery [16] [17] [18] .
is question was intensively studied and discussed during a last decade, and it is not a major subject of this review. Human Proteomics Organisation (HUPO) has developed guidlines for patient data recording, urine collection and sample preparation for several MS based methods (http://www.hupo.org/initiatives/human -kidney-and-urine-proteome-project-hkupp/). A standard method still not commonly used by the proteomics community and most studies use protocols developed to their speci c experiments. Urine samples can be diluted or concentrated depending on their water content, thus requiring normalization of biomarker concentrations. e most common normalization factor is urine creatinine (Cr), but its urinary concentration may vary depending on the level of muscle Cr generation (muscle mass) and renal tubular Cr secretion [19, 20] . e muscle mass depends on age, gender, race, tness and muscle disease, and normalization of urinary samples using Cr can increase protein concentration variability even in the samples collected from healthy individuals. Speci c gravity has also been used for normalization of urine samples [21] . Speci c gravity is the ratio of the weight of a solution to the weight of an equal volume of distilled water. It is strongly in uenced by both the number of particles in the solution and their size. Normalization of urinary proteins using speci c gravity is problematic when large molecules are present in urine. us the best method for urine normalization is still under investigation. Because debris of spontaneously dying renal cells is released into the urine, uncontrolled amounts of intracellular and membrane proteins can be detected especially in highly concentrated samples collected from the patients with epithelial cell injury. Recently, urinary exosomes were used as a potential source of biomarkers of renal diseases [22] [23] [24] [25] . Exosomes are low density inverted apical membrane vesicles normally secreted into the urine from all parts of nephron [22] . ey are smaller than apoptotic vesicles, and can be separated from them by gradient centrifugation. ey have been found to contain many disease-associated proteins including aquaporin-2, polycystin-1, podocin, non-muscle myosin II, angiotensin-converting enzyme, Na+ K+ 2Cl-cotransporter, thiazide-sensitive NaCl cotransporter, and epithelial sodium channel [22] . Exosomes may be usefull for determination of biomarkers for renal dysfunction and structural renal disease [23] . However, the lack of standard e cient methods for vesicle isolation and lysis, and the issue of protein normalization are major limitations for the quantitative proteomics of exosomes [26] [27] [28] .
Despite all these shortcomings, urine is an attractive source of renal diseases biomarkers because of its noninvasiveness, large volume and because its proteins are originated from the kidney and low urinary tract organs.
In recent years the increased capability of the quantitative proteomics was based on the advances in both hardware and so ware methods.
e increased performance capabilities, easy operation, and robustness of MS over other techniques have made it an ideal platform for quantitative proteomics. Novel MS-based quantitative methods o er the opportunity for faster, higher throughput, and a wider dynamic range protein analysis, and can be used for both stable-isotope labeling or label-free methods of protein quanti cation. While several quantitative proteomics approaches exist, each of them has its own advantages and limitations. In this review, we discuss modern quantitative proteomics approaches and their applications for the discovery and validation of urinary biomarkers of renal diseases. We do not describe all urinary biomarkers found by particular MS method but rather concentrate on modern quantitative MS methods and their application for urine proteomics. For each MS method we described only few examples that highlight the usefulness of it for urinary proteomics research.
Two-dimension gel electrophoresis (2DE)
e 2DE method is a primary technique that has been widely used in urinary proteomics [29] [30] [31] . In this gel-based method, urinary proteins are resolved in the rst-dimension based on their isoelectric point (pI) followed by resolution based on molecular weight in the second-dimension. e gels are then stained by either Coomassie Brilliant Blue, silver stain or Sypro Ruby uorescent stain to visualize the protein spots. e important step before the gel separation is urine concentration. Multiple protocols have been developed to concentrate and purify urinary proteins including lyophilization, precipitation, ultracentrifugation, and centrifugal ltration [11, 18, 29, [32] [33] [34] [35] . Analysis of 2DE images is performed using computer-based platforms. Several commercial programs became recently available including Melanie (Geneva Bioinformatics), ImageMaster2D (GE Healthcare), PDQuest (Bio-Rad Laboratories), Dymension (Syngene), SameSpots (Totallab), BioNumerics (Applied Methods) and Delta2D (Decadon). e main steps in di erential analysis of 2DE gels involve image noise substraction, protein spot detection, spot quanti cation, spot matching and statistical analysis. Most programs rst detect spots, estimate spot boundaries, and calculate spot volumes for each individual gel, and then match the detected spots across di erent gels.
is procedure may lead to spot mismatching and missing data, which require manual editing of data. Manual editing signi cantly increases time of analysis, decreases throughput and compromises the objectivity and reproducibility of the analysis [36] . Several novel so ware such as SameSpot (Totallab) and Pinnacle align the images before processing to reduce spot missmatching [37] . It signi cantly reduces time of analysis and increase reproducibility. A er quanti cation analysis protein spots are extracted from the gel and identied by mass spectrometry (peptide mass ngerprinting) [38] . Matrix-assisted laser desorption ionization-time-ofight (MALDI-TOF) mass spectrometry and electrospray ionization (ESI)-MS are most o en used for the identi cation of the extracted proteins. is approach could lead to separation and identi cation of about 2000 unique spots [34, 39] . is approach was successfully used for identi cation of potential biomarkers of di erent renal diseases. High urinary levels of β2-microglobulin, retinol-binding protein, transferrin, hemopexin, haptoglobin, lactoferrin, and neutrophil gelatinase-associated lipocalin (NGAL) were identi ed as candidate biomarkers for HIV-associated nephropathy [40] . Retinol-binding protein was also identi ed as a candidate biomarker for acute tubular necrosis [41] . Retinol-binding protein 4, α-1-microglobulin, zinc-α2 glycoprotein, and α-1B glycoprotein were found to increase in the samples from micro-albuminuric patients with type 1 diabetes [42] .
However, 2DE method has multiple limitations. Both the separation and the analysis are time consuming reducing number of urine samples. Gel to gel variability reduces reproducibility, and requires complex image analysis and manual correction. Importantly, because quanti cation of proteins is performed on the basis of in-gel proteins staining, it depends on the sensitivity of particular stain. e sensitivity of Coomassie Brilliant blue is about 50 ng of protein per spot or 20 ng per spot for colloidal Commassie Blue. Additional variability of results arises from destaining procedure and high background. e sensitivity of silver stain is higher than Coummassie Blue (about 1 ng per spot) but both stains demonstrate poor linear response. Sypro Ruby stain demonstrated similar with silver stain sensitivity (about 1 ng per spot) but less background and good linear response for various protein concentrations. But the sensitivity of in-gel methods is thousand times lower than sensitivity of MSbased methods.
us low reproducibility and low relative quanti cation accuracy are additional obstacles [43] . Also, 2DE has a small dynamic range compared to MS-based methods being mostly suitable for major proteins. ough 2DE has its limitations, it remains a popular method of urinary protein analysis because of its robustness, simplicity and availability in most facilities [44, 45] . Moreover 2DE allows separating and studying proteins isoforms, modi ed proteins and degradated peptides speci c for urine that is di cult to do by MS-based methods.
Two-dimensional di erence gel electrophoresis (2D-DIGE)
e 2D-DIGE method is an improved version of 2DE. In this method, two di erent protein samples (control and a disease) and one internal control (pooled mixture of controls and disease samples in equal proportion) are labeled with three di erent uorophores: Cy2, Cy3, or Cy5 before in gel separation. ese uorophores have the identical charge and molecular mass but unique emission wavelengths that allows identi cation of those uorophores using appropriate optical lters [46] [47] [48] . e labeled samples are then mixed together and separated on a 2DE. e same internal control is used for all samples for normalization. e gel is scanned at three di erent wavelengths: 488 nm (Cy2), 532 nm (Cy3), and 633 nm (Cy5) and relative abundance of proteins are quanti ed using computer so ware such as DeCyder (GE Healthcare Life Science), Melanie (Geneva Bioinformatics) and PDQuest (Bio-Rad). e sensitivity for each uorescent dye is similar to Sypro Ruby uorescent dye (about 1 ng per spot). Addition of internal standards to each gel allows protein normalization and quanti cation of protein amounts as ratios and not as volumes. is method reduces gel-to-gel variation and separates experimental variability form biological one. e quanti cation accuracy of 2D-DIGE is higher than 2DE method. is technique has been routinely used for the discovery of candidate urinary biomarkers of renal disease in patient and animal models [49] [50] [51] [52] . 2D-DIGE-SELDI-TOF (surface-enhanced laser desorption ionizationtime of ight) was used for the detection of early stage tubular injury in canine model of progressive glomerular disease [50] . Alpha 1 antitrypsin was discovered as a diagnostic biomarker for diabetic nephropathy [52] . A number of highly abundant proteins in urine such as albumin fragments have also been identi ed by gel-based proteomics approaches, and these abundant proteins were considered disease-biomarker candidates [53] [54] [55] . Major limitations of this method are time-consuming separation and analysis steps that restricts its use used for high throughput screening. When the number of urine samples is large, cost of uorescent dyes is also an additional limitation. Both 2DE and 2D-DIGE methods have less sensitivity and small dynamic range compared to MS-based methods and are mostly suitable for major proteins.
While 2DE and 2D-DIGE methods employ in-gel quantication based on the protein staining techniques, all other methods described below are MS-based quanti cation techniques (see Table 1 ).
Stable-isotope labeling by amino acids (SILAC)
is method is based on metabolic labeling of proteins with heavy isotopes (H 2 , C 13 , and N 15 ) incorporated into amino acids [56] . A number of amino acids such as arginine, leucine, and lysine with stable isotope are suitable for use in SILAC, but lysine and arginine are the most o en used amino acids, because trypsin-digested peptides contain at least one arginine or lysine making all peptides eligible for quantication [57, 58] . Originally this method was developed for in vitro cell culture [56] . In this method either two di erent lines of cells (experimental and control) are cultured under similar conditions with addition of labeled amino acid to experimental cell line, or cells are cultured under di erent conditions with addition of labeled amino acids to experimental group. Cells are collected a er ve to seven passages to ensure >95% labeling, lysates are prepared, and then experimental and control samples are combined in a 1 : 1 stoichiometric ratio [56] . Combined samples are separated either on 1DE or 2DE following by in-gel digestion, peptides extraction and LC-MS/MS analysis. Alternatively, the samples are digested in-solution and analyzed by LC-MS/MS. Labeled amino acid induces a shi in the mass/charge (m/z) ratio comparing to the unlabelled amino acid. is shi al-lows to discriminate peptides between experimental and control samples, and to quantify relative changes in protein concentration (Fig. 1 A) . Combining the di erentially labeled samples before any puri cation and fractionation steps minimizes the possible quantitative error caused by handling di erent samples in parallel [56] .
Recently, this method has been extended to the animal models [59] [60] [61] . Feeding mice with diet containing a heavy isotope C 13 -lysine for one generation leads to a complete exchange of the natural (light) isotope (12)C6-lysine. Blood, tissue, and organs are labeled, and can be used for global proteomics [62] [63] [64] .
Additionally SILAC can be used for an indirect 'spike-in' approach where cell line is used to produce a heavy-labelled reference sample, which is added as an internal standard to the tissue or organ samples [65] .
SILAC's advantage is that this method does not require a targeted analysis of speci c proteins or peptides because every peptide is labeled and can be quanti ed independently of the degree of resolution and instrument sensitivity. It is also more robust and accurate than other quantitative techniques such as iTRAQ and label-free method [66] . However, SILAC also has several disadvantages. It is di cult and timeconsuming to establish this method in new model organisms. e medium composition has to be controlled and the reagents are expensive. e data analysis is also challenging due to incomplete incorporation of labeled amino acids and arginine-to-proline conversion by arginase [67] . Because arginase II is highly expressed in renal cells, labeled proline incorporation into the proteins increases complexisity of data analysis. Moreover, SILAC cannot be used directly in human samples and has not been used for discovery of human urinary biomarkers.
Investigation of renal cell secretome is a potential step in the urinary biomarker discovery. Treatment of HEK-293 renal cells with cyclosporine demonstrated up-regulation of secreted cyclophilins A and B, macrophage inhibition factor and phosphatidylethanolamine-binding protein 1 [68] . Recently, the SILAC-labeled mouse serum was used for 'spikein' quanti cation of human serum and urine [69] . SILAC mouse serum was mixed with human serum and urine, and multidimensional separation and LC-MS/MS analysis was performed. e shared peptides between two species were quanti ed by SILAC pairs. Analysis of urine from immunoglobulin A nephropathy patients identi ed novel biomarker candidates, such as Complement C3, Albumin, VDBP, ApoA1, and IGFBP7 [69] . us, despite the fact that SILAC cannot be used directly in human samples, its application in Table 1 . Quantitative methods to analyze urinary biomarkers renal cell secretome and animal models can potentially lead to the discovery candidates biomarkers of renal disease.
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)
iTRAQ is a method of in vitro peptides labeling a er trypsin digestion of proteins that allowed to compare multiple samples in one MS/MS run [70] [71] [72] . iTRAQ label consists of a reporter group with a de ned molecular weight, a balance group, and an amine-reactive group that reacts at lysine side chains and NH 2 15 N, and 18 O atoms in such way that all peptides with di erent iTRAQ labels attached are isobaric (same mass) and indistinguishable in chromatographic separation and MS. e function of balance groups is to make all iTRAQ tags isobaric so the combined mass of reporter group and balance group remains constant. Following fragmentation in MS/MS the iTRQ label looses the balance group, while the charge is retained by the reporter group. e eight reporter group ions appear as distinct masses in MS/MS that can be used to identify and quantify individual members of the multiplex set [70] . In iTRAQ, up to eight (8-plex) samples are labeled a er trypsin digestion with iTRAQ reagents. e samples then are pooled together, the labeled peptides are separated by strong cation exchange chromatography, and the isolated labeled peptides are separated by LC-MS/ MS [73] . Di erent samples can be run together in the single MS/MS run. e isobaric nature of the tags allows the pro- . Samples are combined together and LC-MS/MS is performed. Identical peptides labeled with the di erent iTRAQ tags produce the same peak in MS spectra (shown in rectangle). MS/MS fragmentation of ion produces unique peak for each tag that allowed comparison of relative intensity. (C) Label-free quanti cation using SIEVE program. Sample (red color) and control (blue color) are processed separately and LC-MS/MS is performed. SIEVE program from ermo Electron perform aliment of peaks, peak area integration and spectral counting, that quantify relative amount of protein in sample. tein samples to be pooled together a er labeling without increasing the complexity of the MS analysis. Identical peptides labeled with the di erent iTRAQ reagents produce the same peak (ion) in MS spectra. Upon MS/MS fragmentation of the parent ion, unique signature ions are generated which distinguish the individual samples and allow to compare the relative amount of each sample (Fig. 1B) . iTRAQ method can also be used for absolute quanti cation of peptides by adding an internal standard peptide.
e advantage of iTRAQ labeling is that the signal obtained from combined peptides enhances the sensitivity of detection in MS/MS. However, the variability in labeling e ciencies and the costly reagents are major limitations of this method [74] . Labeling also increases complexity of the samples and can reduce number of the identi ed peptides during MS/MS run. Some peptides are lost during the separation on SCX chromatography. Recently, electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) have been developed as an alternative to the SCX chromatography [75] . ERLIC method separates peptides on the basis of electrostatic repulsion and hydrophilic interaction and is found to increase the proteome coverage.
e use of this powerful technique is gradually becoming the method of choice in the eld of biomarker discovery [3, [76] [77] [78] . is method allowed discovering P-and E-cadherins as urinary biomarkers of idiopathic nephrotic syndrome [76] . Alpha-1-antitrypsin, alpha-1-acid glycoprotein 1, and prostate stem cell antigen has been discovered as candidate biomarkers for diabetic nephropathy [77] . Uromodulin, SERPINF1, and CD44 were identi ed and veri ed in an independent cohort as urinary biomarkers to di erentiate patients with early acute kidney transplant rejection from other groups [78] .
Label-free quantitative methods
To overcome the problems in the labeling techniques such as high cost of the reagents, higher concentration of sample requirement, and incomplete labeling, label-free shotgun proteomic technologies have been developed. ese methods are based on the assumption that the peak area of a peptide in the chromatogram is directly proportional to its concentration [79] [80] [81] . Label-free protein quanti cation approach is based on two types of measurements; the measurement of ion intensity by quanti cation of peptide peak areas or peak heights in chromatogram, and the spectral counting in the MS/MS analysis. For spectral counting, peptides from the same protein are identi ed, chromatographic peaks aligned and normalized (Fig.1C) .
ere are several commercially available so ware packages for label-free analysis (Decyder MS from GE Healthcare, Protein Lynx from Waters, and SIEVE from ermo Electron).
is approach is primarily used for the analysis of human samples and has been applied to the analysis of urinary proteome [1, 82, 83] . It is a very high throughput technique that increases opportunities in the discovery of candidate biomarkers.
ere are several advantages in label-free quanti cation approach. It is a cheap method comparing to the labeling techniques. It is simpler in terms of sample preparation, and less complicated in terms of MS/MS analysis [81] . e limitation of this method is redundancy in peak detection which arises from the peptides which are similar for several proteins [84] . Other limitations of label-free quanti cation methods are less accuracy, semi-quantitative nature, and unsuitability for low abundance and small proteins [85] . Small proteins or proteins of low abundance could still be present in the sample in spite of the spectral count being zero, larger proteins generate more tryptic digest products, and more spectral counts. Another limitation of the method is a spectra normalization. In contrast to SILAC and iTRAQ methods, in label-free method the spectra are generated in separate MS/MS runs that are di erent in many factors like e ciency of fragmentation and ionization [85] . Label-free quanti cation methods overcome those limitations by additional computational calculations. ere are several algorithms available that take into account the sequence and length of the peptides and compute the predicted abundance of proteins in the sample [86] [87] [88] . Protein abundance index (PAI) is de ned as the number of identi ed peptides divided by the number of theoretically observable tryptic peptides for each protein. Absolute quanti cation of proteins is based on exponentially modi ed PAI values with or without added standards [79, 85] . Label-free quantitative analysis of urinary exosomes in diabetic nephropathy resulted in the discovery of three proteins AMBP, MLL3 and VDAC1 as candidate biomarkers [24] . Another group of proteins (Tamm-Horsfall glycoprotein, progranulin, clusterin and α-1 acid glycoprotein) were determined as candidate biomarkers for microalbuminuria progression in diabetic nephropathy [89] .
MS-based absolute quanti cation methods for biomarkers validation
e methods described above have been used mostly for urinary biomarkers discovery. Traditional methods such as Western blot and Elisa are the rst choice for validation of biomarkers, but novel stable isotope dilution MS (SID-MS) quanti cation methods suitable for validation have been developed. Two methods (selected reaction monitoring (SRM), and multiple-reaction monitoring (MRM)) have been used for absolute quanti cation of proteins in combination with stable isotope dilution. ese methods are based on the addition of known quantities of isotope-labeled standards, which have similar chromatographic properties to the target compounds but can be distinguished from them by their di erence in m/z [90, 91] .
e isotope dilution method is a targeted approach focused on a limited set of proteins.
e identi cation of candidate proteins requires the prior generation of isotope-labeled standards [92, 93] . Quanti cation is performed by comparing the peak height or peak area of the isotope-labeled and the native forms of a peptide of interest. SRM is a non-scanning mass spectrometry technique, performed on triple quadrupole instruments. In SRM experiments, two mass analyzers are used as static mass lters, to monitor a particular fragment ion of a selected precursor ion. e speci c pair of m/z values associated with the precursor and fragment ions selected are referred to as a "transition" [94] . Unlike common MS based proteomics, no mass spectra are recorded in a SRM analysis. Instead, the detector acts as a counting device for the ions matching the selected transition thereby returning an intensity value over time. In MRM experiment, multiple transitions can be measured within the same experiment on the chromatographic time scale by rapidly shi ing between the di erent precursor/fragment pairs. Typically, a triple quadrupole instrument cycles through a series of transitions and records the signal of each transition as a function of the elution time.
e major advantage of these methods is good linearity and excellent precision, but the accuracy and ability to determine the true abundance of target protein strongly depends on the choice of selected peptides and the purity of internal standards [95, 96] . is method covers a complete dynamic range of cellular proteome, with a low limit of detection below. 50 copies of protein per cell [97] . e disadvantage of these methods is that they are limited to a small number of proteins because suitable internal standards have to be purchased or synthesized. SID-MS based quanti cation is lling the gap between the discovery and validation of biomarkers that may promote candidate biomarkers towards clinical trials and established them as diagnostic tools. However, developing and validating SID-MS-based assays is an expensive and time consuming process, requiring a coordinated and collaborative e ort by the scienti c community through the sharing of publicly accessible data and datasets, bioinformatic tools, standard operating procedures, and well characterized reagents [98] .
ere are several examples of recent coordinated e orts for development of urinary biomarkers for renal diseases.
e Nephrotoxicity Working Group of the Predictive Safety Testing Consortium have selected 23 previously discovered urinary biomarkers and evaluated them in rat models of acute kidney injury (AKI) [99] [100] [101] [102] [103] . Seven markers were selected for further preclinical studies, including: kidney injury molecule-1 (kim-1), albumin, total protein, β 2 -microglobulin, cystatin C, clusterin, and trefoil factor-3. Chronic kidney disease (CKD) consortium (www.ckdbiomarkersconsortium.org) have identi ed fourteen candidate biomarkers for CDK progression and twelve biomarkers for early stage CKD in diabetes and lupus nephrology [104, 105] . Future coordinated e orts from scienti c community will validate recently discovered biomarkers of renal diseases.
Concluding Remarks
Nephrology is in a dire need for improved diagnostic and therapeutic markers. Despite the more than a decade of intensive investigation of urinary biomarkers no new clinical biomarkers were approved [106] . Similar to the early genomic studies, expectations toward proteomics in biomarkers discovery were signi cantly higher than the ability of the technology a decade ago. e technology was underdeveloped with limited analytical and quanti cation capability. us early investigations in this area were largely conned to measurement of major urinary proteins without association with disease mechanisms. Now it is clear that the most promising biomarkers have been found in welldesigned studies guided by speci c research questions. Moreover, during the last decade, proteomic technology has made dramatic progress in both the hardware and so ware methods [107] . Advances in quantitative proteomics and development of SRM and MRM methods let the proteinquanti cation data stand by their own without validation from other protein quanti cation methods as Western blot and Elisa [108] . is progress opens a new era in the discovery and validation of urinary biomarkers of renal disease. Collaborative e orts by the scienti c community are needed for the development of standardized protocols for sample preparation methods suitable for examination of lowabundance urinary proteins. Addition of other indirect approaches, such as cell cultures and animals models, may be useful for the discovery of potential biomarker candidates that could be subsequently found in urines. Uncovering of disease molecular mechanisms may predict new candidate urinary biomarkers.
